Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice

With the increasing obesity prevalence, the rates of obesity-related diseases, including type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases, have increased dramatically. Dapagliflozin, one of the sodium glucose cotransporter inhibitors, not only exerts hypoglycae...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Tuo, Fan, Yajie, Gao, Jie, Fatima, Mahreen, Zhang, Yali, Ding, Yiming, Bai, Liang, Wang, Congxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475578/
https://www.ncbi.nlm.nih.gov/pubmed/34550043
http://dx.doi.org/10.1080/21623945.2021.1979277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475578/
https://www.ncbi.nlm.nih.gov/pubmed/34550043
http://dx.doi.org/10.1080/21623945.2021.1979277

Ejemplares similares